A randomized phase III trial that assessed treatment with cisplatin plus gemcitabine or gemcitabine alone for patients with advanced biliary tract cancer has provided evidence for a new standard treatment option for these patients. The therapeutic outcome (that is, overall survival, disease-free survival, and disease control rate), was significantly better in the combination arm with no increase in toxic effects.
